{
    "clinical_study": {
        "@rank": "62046", 
        "arm_group": {
            "arm_group_label": "Bortezomib", 
            "arm_group_type": "Experimental", 
            "description": "Bortezomib 1.3 milligram (mg) per meter square (m^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this post marketing study is to determine the plasma concentration of\n      bortezomib (unchanged drug) to assess the pharmacokinetic (PK - the study of the way a drug\n      enters and leaves the blood and tissues over time) properties in the Taiwanese population.\n      It will also provide expanded access (expanded access, sometimes called \"compassionate use,\"\n      is the use of an investigational drug outside of a clinical trial to treat a participant\n      with a serious or immediately life-threatening disease or condition who has no comparable or\n      satisfactory alternative treatment options) to bortezomib for the same group of participants\n      with multiple myeloma (cancer of the types of cells normally found in bone marrow)."
        }, 
        "brief_title": "A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                        "title": "Bortezomib"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "14"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "8.31", 
                                            "@value": "62.63"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "Years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "8"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "6"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "Participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "7"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "Complete response"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "Response"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "Partial Response"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "Stable disease"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "Progression"
                                            }
                                        ]
                                    }, 
                                    "description": "Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With Response to Treatment at Day 1 of Cycle 5", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "The full analysis set (FAS) population included all the participants who received 1 dose of study medication and had post-dose efficacy data. Here \u2018N\u2019 signifies those participants who were evaluated for this outcome measures.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 of Cycle 5", 
                        "title": "Number of Participants With Response to Treatment at Day 1 of Cycle 5", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "5"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "Response"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "3"
                                                    }
                                                }, 
                                                "sub_title": "Partial Response"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "Stable disease"
                                            }
                                        ]
                                    }, 
                                    "description": "Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With Response to Treatment at Day 1 of Cycle 7", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "The FAS population included all the participants who received 1 dose of study medication and had post-dose efficacy data. Here \u2018N\u2019 signifies those participants who were evaluated for this outcome measures.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 of Cycle 7", 
                        "title": "Number of Participants With Response to Treatment at Day 1 of Cycle 7", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "14"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "Response"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "3"
                                                    }
                                                }, 
                                                "sub_title": "Partial response"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "Minimal response"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "Stable disease"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }
                                                }, 
                                                "sub_title": "Progression"
                                            }
                                        ]
                                    }, 
                                    "description": "Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With Response to Treatment at Day 11 of Cycle 8", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "The FAS population included all the participants who received 1 dose of study medication and had post-dose efficacy data.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 11 of Cycle 8", 
                        "title": "Number of Participants With Response to Treatment at Day 11 of Cycle 8", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "14"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 70"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "3"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 80"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "7"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 90"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 100"
                                            }
                                        ]
                                    }, 
                                    "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With Karnofsky Performance Status (KPS) Score at Baseline", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "The FAS population included all the participants who received 1 dose of study medication and had post-dose efficacy data.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline", 
                        "title": "Number of Participants With Karnofsky Performance Status (KPS) Score at Baseline", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "14"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 70"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "5"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 80"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "5"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 90"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 100"
                                            }
                                        ]
                                    }, 
                                    "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With KPS Score at Day 1 of Cycle 1", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "The FAS population included all the participants who received 1 dose of study medication and had post-dose efficacy data.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 of Cycle 1", 
                        "title": "Number of Participants With KPS Score at Day 1 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "12"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 60"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 70"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 80"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 90"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 100"
                                            }
                                        ]
                                    }, 
                                    "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With KPS Score at Day 1 of Cycle 3", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "The FAS population included all the participants who received 1 dose of study medication and had post-dose efficacy data. Here \u2018N\u2019 signifies those participants who were evaluated for this outcome measures.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 of Cycle 3", 
                        "title": "Number of Participants With KPS Score at Day 1 of Cycle 3", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "7"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 60"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 70"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "4"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 80"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 100"
                                            }
                                        ]
                                    }, 
                                    "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With KPS Score at Day 1 of Cycle 5", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "The FAS population included all the participants who received 1 dose of study medication and had post-dose efficacy data. Here \u2018N\u2019 signifies those participants who were evaluated for this outcome measures.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 of Cycle 5", 
                        "title": "Number of Participants With KPS Score at Day 1 of Cycle 5", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "5"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 60"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 80"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 90"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 100"
                                            }
                                        ]
                                    }, 
                                    "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With KPS Score at Day 1 of Cycle 7", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "The FAS population included all the participants who received 1 dose of study medication and had post-dose efficacy data. Here \u2018N\u2019 signifies those participants who were evaluated for this outcome measures.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 of Cycle 7", 
                        "title": "Number of Participants With KPS Score at Day 1 of Cycle 7", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "14"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 50"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "4"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 60"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 70"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "3"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 80"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 90"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "KPS Score = 100"
                                            }
                                        ]
                                    }, 
                                    "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With KPS Score at Day 11 of Cycle 8", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "The FAS population included all the participants who received 1 dose of study medication and had post-dose efficacy data.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 11 of Cycle 8", 
                        "title": "Number of Participants With KPS Score at Day 11 of Cycle 8", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The Cmax is observed maximum plasma concentration, taken directly from the plasma concentration-time profile.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "38.47", 
                                                    "@value": "76.43"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The Cmax is observed maximum plasma concentration, taken directly from the plasma concentration-time profile.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 1 of Cycle 1", 
                                    "units": "Nanogram per millileter (ng per ml)"
                                }
                            ]
                        }, 
                        "population": "The Per-protocol (PP) population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1", 
                        "title": "Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 1 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The Cmax is observed maximum plasma concentration, taken directly from the plasma concentration-time profile.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "59.80", 
                                                    "@value": "127.02"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The Cmax is observed maximum plasma concentration, taken directly from the plasma concentration-time profile.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 11 of Cycle 1", 
                                    "units": "ng per ml"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1", 
                        "title": "Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 11 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Tmax is the time when Cmax is observed, taken directly from the plasma concentration-time profile.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "0.00", 
                                                    "@value": "0.08"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Tmax is the time when Cmax is observed, taken directly from the plasma concentration-time profile.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 1 of Cycle 1", 
                                    "units": "Hours"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1", 
                        "title": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 1 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Tmax is the time when Cmax is observed, taken directly from the plasma concentration-time profile.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "0.01", 
                                                    "@value": "0.08"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Tmax is the time when Cmax is observed, taken directly from the plasma concentration-time profile.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 11 of Cycle 1", 
                                    "units": "Hours"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1", 
                        "title": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 11 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda[z]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "0.07", 
                                                    "@value": "0.08"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda[z]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Elimination Half-Life Period (T1/2) of Bortezomib on Day 1 of Cycle 1", 
                                    "units": "Hours"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1", 
                        "title": "Elimination Half-Life Period (T1/2) of Bortezomib on Day 1 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda[z]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "87.20", 
                                                    "@value": "51.55"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda[z]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Elimination Half-Life Period (T1/2) of Bortezomib on Day 11 of Cycle 1", 
                                    "units": "Hours"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1", 
                        "title": "Elimination Half-Life Period (T1/2) of Bortezomib on Day 11 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Lambda(z) is defined as terminal rate-constant which reflect the speed of drug elimination in vivo (within the living), and is estimated by log-linear regression analysis of the terminal phase of the plasma concentration versus time curve for at least 3 points.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "0.07", 
                                                    "@value": "0.08"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Lambda(z) is defined as terminal rate-constant which reflect the speed of drug elimination in vivo (within the living), and is estimated by log-linear regression analysis of the terminal phase of the plasma concentration versus time curve for at least 3 points.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 1 of Cycle 1", 
                                    "units": "Per Hour"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1", 
                        "title": "Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 1 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Lambda(z) is defined as terminal rate-constant which reflect the speed of drug elimination in vivo (within the living), and is estimated by log-linear regression analysis of the terminal phase of the plasma concentration versus time curve for at least 3 points.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "0.01", 
                                                    "@value": "0.01"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Lambda(z) is defined as terminal rate-constant which reflect the speed of drug elimination in vivo (within the living), and is estimated by log-linear regression analysis of the terminal phase of the plasma concentration versus time curve for at least 3 points.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 11 of Cycle 1", 
                                    "units": "Per Hour"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1", 
                        "title": "Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 11 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The AUC(0-t) is area under the plasma concentration-time curve from time zero to the last quantifiable concentration determined by the trapezoidal rule.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "30.56", 
                                                    "@value": "51.86"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The AUC(0-t) is area under the plasma concentration-time curve from time zero to the last quantifiable concentration determined by the trapezoidal rule.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 1 of Cycle 1", 
                                    "units": "Hour*ng per ml"
                                }
                            ]
                        }, 
                        "population": "PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1", 
                        "title": "Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 1 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The AUC(0-t) is area under the plasma concentration-time curve from zero to the last quantifiable concentration determined by the trapezoidal rule.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "55.27", 
                                                    "@value": "190.39"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The AUC(0-t) is area under the plasma concentration-time curve from zero to the last quantifiable concentration determined by the trapezoidal rule.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 11 of Cycle 1", 
                                    "units": "Hour*ng per mL"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1", 
                        "title": "Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 11 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "126.91", 
                                                    "@value": "106.99"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 1 of Cycle 1", 
                                    "units": "Hour*ng per ml"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 of Cycle 1", 
                        "title": "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 1 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "178.81", 
                                                    "@value": "349.62"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 11 of Cycle 1", 
                                    "units": "Hour*ng per ml"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1", 
                        "title": "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 11 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "AUMC is defined as the area under first moment plasma concentration-time curve from time of dosing up to definite time t, to infinity, or to the time of last measurable concentration determined by the following equation: AUMC(0 to infinity)=Cntn/k elimination(el) + Cn/k(el^2) summation[(tn \u2013 tn^-1) (Cn^-1) (tn^-1)] + Cntn/2 where Cn=last quantifiable concentration, tn=time at which Cn is measured, k=rate constant.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "54596.1", 
                                                    "@value": "20678.41"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "AUMC is defined as the area under first moment plasma concentration-time curve from time of dosing up to definite time t, to infinity, or to the time of last measurable concentration determined by the following equation: AUMC(0 to infinity)=Cntn/k elimination(el) + Cn/k(el^2) summation[(tn \u2013 tn^-1) (Cn^-1) (tn^-1)] + Cntn/2 where Cn=last quantifiable concentration, tn=time at which Cn is measured, k=rate constant.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 1 of Cycle 1", 
                                    "units": "Hour square*ng per ml"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1", 
                        "title": "Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 1 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "AUMC is defined as the area under first moment plasma concentration-time curve from time of dosing up to definite time t, to infinity, or to the time of last measurable concentration determined by the following equation: AUMC(0 to infinity)=Cntn/k elimination(el) + Cn/k(el^2) summation[(tn \u2013 tn^-1) (Cn^-1) (tn^-1)] + Cntn/2 where Cn=last quantifiable concentration, tn=time at which Cn is measured, k=rate constant.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "51021.07", 
                                                    "@value": "39414.06"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "AUMC is defined as the area under first moment plasma concentration-time curve from time of dosing up to definite time t, to infinity, or to the time of last measurable concentration determined by the following equation: AUMC(0 to infinity)=Cntn/k elimination(el) + Cn/k(el^2) summation[(tn \u2013 tn^-1) (Cn^-1) (tn^-1)] + Cntn/2 where Cn=last quantifiable concentration, tn=time at which Cn is measured, k=rate constant.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 11 of Cycle 1", 
                                    "units": "Hour square*ng per ml"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1", 
                        "title": "Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 11 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "121.65", 
                                                    "@value": "65.97"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Mean Residence Time (MRT) of Bortezomib in the Body on Day 1 of Cycle 1", 
                                    "units": "Hour"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1", 
                        "title": "Mean Residence Time (MRT) of Bortezomib in the Body on Day 1 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "58.38", 
                                                    "@value": "88.74"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Mean Residence Time (MRT) of Bortezomib in the Body on Day 11 of Cycle 1", 
                                    "units": "Hour"
                                }
                            ]
                        }, 
                        "population": "PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1", 
                        "title": "Mean Residence Time (MRT) of Bortezomib in the Body on Day 11 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "18.54", 
                                                    "@value": "25.99"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Systemic Clearance (CL) of Bortezomib on Day 1 of Cycle 1", 
                                    "units": "Liter per Hour"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1", 
                        "title": "Systemic Clearance (CL) of Bortezomib on Day 1 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "2.46", 
                                                    "@value": "4.68"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Systemic Clearance (CL) of Bortezomib on Day 11 of Cycle 1", 
                                    "units": "Liter per Hour"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1", 
                        "title": "Systemic Clearance (CL) of Bortezomib on Day 11 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by (D/AUC[0-infinity])*(AUMC[0-infinity])/AUC[0-infinity]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "403.04", 
                                                    "@value": "483.71"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by (D/AUC[0-infinity])*(AUMC[0-infinity])/AUC[0-infinity]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 1 of Cycle 1", 
                                    "units": "Liter"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1", 
                        "title": "Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 1 of Cycle 1", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by (D/AUC[0-infinity])*(AUMC[0-infinity])/AUC[0-infinity]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                                "title": "Bortezomib"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "10"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "85.81", 
                                                    "@value": "331.68"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by (D/AUC[0-infinity])*(AUMC[0-infinity])/AUC[0-infinity]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 11 of Cycle 1", 
                                    "units": "Liter"
                                }
                            ]
                        }, 
                        "population": "The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.", 
                        "safety_issue": "No", 
                        "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1", 
                        "title": "Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 11 of Cycle 1", 
                        "type": "Primary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Participants received 1.3 milligram per meter square (mg per m^2) of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                        "title": "Bortezomib"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "3", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Withdrawal by Subject"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "2", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Adverse Event"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "4", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Progressive disease"
                                }
                            ]
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "14", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "5", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "9", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }
            }, 
            "point_of_contact": {
                "name_or_title": "Medical Affairs Director", 
                "organization": "Janssen Pharmaceutical Taiwan", 
                "phone": "+886-2-23762155"
            }, 
            "reported_events": {
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Participants received 1.3 mg per m^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
                        "title": "Bortezomib"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "14", 
                                            "@subjects_at_risk": "14"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "14"
                                        }, 
                                        "sub_title": "Tachycardia"
                                    }
                                }, 
                                "title": "Cardiac disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Abdominal distension"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Abdominal pain upper"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Colitis"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "7", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Constipation"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "8", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Diarrhoea"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Dyspepsia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Gingival ulceration"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Ileus"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Nausea"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Oesophageal ulcer"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Vomiting"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Abdominal pain"
                                        }
                                    ]
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Chest pain"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Irritability"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Localised oedema"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Nodule"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Oedema"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Oedema peripheral"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Pain"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "7", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Pyrexia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Fatigue"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Device related infection"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Herpes simplex"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Herpes zoster"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Infections - pathogen unspecified"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Oral candidiasis"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Salmonella bacteraemia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Upper respiratory tract infection"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Urinary tract infection"
                                        }
                                    ]
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Excoriation"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Fracture"
                                        }
                                    ]
                                }, 
                                "title": "Injury, poisoning and procedural complications"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Alanine aminotransferase increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "7", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Aspartate aminotransferase increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood albumin decreased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood alkaline phosphatase increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood amylase increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood calcium decreased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood calcium increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood cholesterol increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood creatinine abnormal"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood creatinine increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood glucose increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood lactate dehydrogenase increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood magnesium decreased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood magnesium increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood phosphorus decreased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood potassium decreased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood sodium increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood triglycerides increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood uric acid increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Gamma-glutamyltransferase increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "9", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Haemoglobin decreased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "11", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Neutrophil count decreased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "10", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Platelet count decreased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Weight decreased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "11", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "White blood cell count decreased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood potassium increased"
                                        }
                                    ]
                                }, 
                                "title": "Investigations"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Anorexia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Hyperlipidaemia"
                                        }
                                    ]
                                }, 
                                "title": "Metabolism and nutrition disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Back pain"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Muscular weakness"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Musculoskeletal pain"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Neck pain"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Pain in extremity"
                                        }
                                    ]
                                }, 
                                "title": "Musculoskeletal and connective tissue disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "14"
                                        }, 
                                        "sub_title": "Thyroid neoplasm"
                                    }
                                }, 
                                "title": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Dizziness"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Headache"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Hypoaesthesia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Nervous system disorder"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "7", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Neuralgia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Tremor"
                                        }
                                    ]
                                }, 
                                "title": "Nervous system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Anxiety"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Confusional state"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Depression"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Insomnia"
                                        }
                                    ]
                                }, 
                                "title": "Psychiatric disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Dysuria"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Renal failure"
                                        }
                                    ]
                                }, 
                                "title": "Renal and urinary disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Cough"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Pharyngolaryngeal pain"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Pleural effusion"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Rhinorrhoea"
                                        }
                                    ]
                                }, 
                                "title": "Respiratory, thoracic and mediastinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Dermatitis"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Exfoliative rash"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Pruritus"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Urticaria"
                                        }
                                    ]
                                }, 
                                "title": "Skin and subcutaneous tissue disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Hypertension"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Hypotension"
                                        }
                                    ]
                                }, 
                                "title": "Vascular disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA V 10.0", 
                    "frequency_threshold": "0"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "14", 
                                            "@subjects_at_risk": "14"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "14"
                                        }, 
                                        "sub_title": "Pancytopenia"
                                    }
                                }, 
                                "title": "Blood and lymphatic system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Gastritis"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Mouth ulceration"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Nausea"
                                        }
                                    ]
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "14"
                                        }, 
                                        "sub_title": "Fatigue"
                                    }
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Pneumonia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Sepsis"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Urinary tract infection"
                                        }
                                    ]
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Ammonia abnormal"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood albumin decreased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood antidiuretic hormone abnormal"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood calcium increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood glucose decreased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood potassium decreased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Blood sodium increased"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Mini mental status examination abnormal"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Platelet count decreased"
                                        }
                                    ]
                                }, 
                                "title": "Investigations"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "14"
                                        }, 
                                        "sub_title": "Back pain"
                                    }
                                }, 
                                "title": "Musculoskeletal and connective tissue disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "14"
                                        }, 
                                        "sub_title": "Neoplasm progression"
                                    }
                                }, 
                                "title": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Haemorrhage intracranial"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "14"
                                            }, 
                                            "sub_title": "Syncope"
                                        }
                                    ]
                                }, 
                                "title": "Nervous system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "14"
                                        }, 
                                        "sub_title": "Confusional state"
                                    }
                                }, 
                                "title": "Psychiatric disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "14"
                                        }, 
                                        "sub_title": "Acute pulmonary oedema"
                                    }
                                }, 
                                "title": "Respiratory, thoracic and mediastinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "14"
                                        }, 
                                        "sub_title": "Hypotension"
                                    }
                                }, 
                                "title": "Vascular disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA V 10.0"
                }, 
                "time_frame": "Basleine up to Day 11 of Cycle 8"
            }
        }, 
        "completion_date": {
            "#text": "April 2008", 
            "@type": "Actual"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label (all people know the identity of the intervention), single-arm,\n      multi-center (conducted in more than 1 center) study to assess the PK of bortezomib and to\n      provide expanded access  to bortezomib for 14 Taiwanese participants with multiple myeloma\n      who have received at least 2 previous lines of therapy (medicine or medical care given to a\n      participant for a disease or condition) and are refractory (not responding to treatment) to\n      or have relapsed (the return of a medical problem) after their last therapy. Eligible\n      participants will receive bortezomib 1.3 milligram (mg) per meter square (m^2) on Days 1, 4,\n      8, and 11 of each 3-week cycle for up to 8 cycles. Blood samples for PK assessment will be\n      collected on specified time points of Day 1, Day 8, and Day 11 of Cycle 1. Efficacy of the\n      participants will primarily be evaluated by recording 'response to treatment' and 'Karnofsky\n      Performance Status'. Participants' safety will be monitored throughout the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants previously diagnosed with multiple myeloma based on standard criteria\n\n          -  Participant has received at least 2 previous lines of therapy for multiple myeloma\n             and, in the Investigator's opinion, currently requires therapy because of relapsed\n             (the return of a medical problem) or progressive disease\n\n          -  Female participants either postmenopausal or surgically sterilized or willing to use\n             an acceptable method of birth control from Screening through the Final Visit\n\n          -  If male, the participant agrees to use an acceptable barrier method for contraception\n             from Screening through the Final Visit\n\n          -  Participant has a Karnofsky performance status classifies participants as to their\n             functional impairment and is used to compare effectiveness of different therapies and\n             to assess the prognosis [outlook, probable outcomes] in individual participants)\n             greater than 60\n\n        Exclusion Criteria:\n\n          -  If the participant received bortezomib in a previous trial, the Participants' best\n             response to bortezomib must be progressive disease\n\n          -  If the participant received bortezomib in a previous trial, the participant must have\n             experienced 1 or more serious adverse events\n\n          -  Participants who have received nitrosoureas within 6 weeks or any other chemotherapy\n             (treatment of disease, usually cancer, by chemical agents) within 3 weeks before\n             enrollment\n\n          -  Participants who have received corticosteroids  (greater than 10 milligram per day\n             prednisone or equivalent) within 3 weeks before enrollment\n\n          -  Human Immunodeficiency Virus (HIV - a life-threatening infection which you can get\n             from an infected person's blood or from having sex with an infected person)-positive\n             or hepatitis-B surface antigen-positive participants or participants with known\n             active hepatitis-C infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 27, 2013", 
        "firstreceived_results_date": "March 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01801436", 
            "org_study_id": "CR013843", 
            "secondary_id": "26866138MMY3014"
        }, 
        "intervention": {
            "arm_group_label": "Bortezomib", 
            "description": "Bortezomib 1.3 mg per (m^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.", 
            "intervention_name": "Bortezomib", 
            "intervention_type": "Drug", 
            "other_name": "VELCADE"
        }, 
        "intervention_browse": {
            "mesh_term": "Bortezomib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Multiple Myeloma", 
            "Bortezomib", 
            "Velcade"
        ], 
        "lastchanged_date": "March 28, 2013", 
        "number_of_arms": "1", 
        "official_title": "A Post Approval Commitment Study for Pharmacokinetic Analysis and Providing Expanded Access to Bortezomib (Velcade) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma in Taiwan", 
        "overall_official": {
            "affiliation": "Johnson & Johnson Taiwan Ltd", 
            "last_name": "Johnson & Johnson Taiwan Ltd Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Taiwan: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.", 
                "measure": "Number of Participants With Response to Treatment at Day 1 of Cycle 5", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 5"
            }, 
            {
                "description": "Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.", 
                "measure": "Number of Participants With Response to Treatment at Day 1 of Cycle 7", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 7"
            }, 
            {
                "description": "Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.", 
                "measure": "Number of Participants With Response to Treatment at Day 11 of Cycle 8", 
                "safety_issue": "No", 
                "time_frame": "Day 11 of Cycle 8"
            }, 
            {
                "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                "measure": "Number of Participants With Karnofsky Performance Status (KPS) Score at Baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                "measure": "Number of Participants With KPS Score at Day 1 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 1"
            }, 
            {
                "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                "measure": "Number of Participants With KPS Score at Day 1 of Cycle 3", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 3"
            }, 
            {
                "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                "measure": "Number of Participants With KPS Score at Day 1 of Cycle 5", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 5"
            }, 
            {
                "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                "measure": "Number of Participants With KPS Score at Day 1 of Cycle 7", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 7"
            }, 
            {
                "description": "The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.", 
                "measure": "Number of Participants With KPS Score at Day 11 of Cycle 8", 
                "safety_issue": "No", 
                "time_frame": "Day 11 of Cycle 8"
            }, 
            {
                "description": "The Cmax is observed maximum plasma concentration, taken directly from the plasma concentration-time profile.", 
                "measure": "Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 1 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1"
            }, 
            {
                "description": "The Cmax is observed maximum plasma concentration, taken directly from the plasma concentration-time profile.", 
                "measure": "Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 11 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1"
            }, 
            {
                "description": "Tmax is the time when Cmax is observed, taken directly from the plasma concentration-time profile.", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 1 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1"
            }, 
            {
                "description": "Tmax is the time when Cmax is observed, taken directly from the plasma concentration-time profile.", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 11 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1"
            }, 
            {
                "description": "The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda[z]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).", 
                "measure": "Elimination Half-Life Period (T1/2) of Bortezomib on Day 1 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1"
            }, 
            {
                "description": "The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda[z]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).", 
                "measure": "Elimination Half-Life Period (T1/2) of Bortezomib on Day 11 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1"
            }, 
            {
                "description": "Lambda(z) is defined as terminal rate-constant which reflect the speed of drug elimination in vivo (within the living), and is estimated by log-linear regression analysis of the terminal phase of the plasma concentration versus time curve for at least 3 points.", 
                "measure": "Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 1 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1"
            }, 
            {
                "description": "Lambda(z) is defined as terminal rate-constant which reflect the speed of drug elimination in vivo (within the living), and is estimated by log-linear regression analysis of the terminal phase of the plasma concentration versus time curve for at least 3 points.", 
                "measure": "Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 11 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1"
            }, 
            {
                "description": "The AUC(0-t) is area under the plasma concentration-time curve from time zero to the last quantifiable concentration determined by the trapezoidal rule.", 
                "measure": "Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 1 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1"
            }, 
            {
                "description": "The AUC(0-t) is area under the plasma concentration-time curve from zero to the last quantifiable concentration determined by the trapezoidal rule.", 
                "measure": "Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 11 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1"
            }, 
            {
                "description": "The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.", 
                "measure": "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 1 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 1"
            }, 
            {
                "description": "The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.", 
                "measure": "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 11 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1"
            }, 
            {
                "description": "AUMC is defined as the area under first moment plasma concentration-time curve from time of dosing up to definite time t, to infinity, or to the time of last measurable concentration determined by the following equation: AUMC(0 to infinity)=Cntn/k elimination(el) + Cn/k(el^2) summation[(tn - tn^-1) (Cn^-1) (tn^-1)] + Cntn/2 where Cn=last quantifiable concentration, tn=time at which Cn is measured, k=rate constant.", 
                "measure": "Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 1 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1"
            }, 
            {
                "description": "AUMC is defined as the area under first moment plasma concentration-time curve from time of dosing up to definite time t, to infinity, or to the time of last measurable concentration determined by the following equation: AUMC(0 to infinity)=Cntn/k elimination(el) + Cn/k(el^2) summation[(tn - tn^-1) (Cn^-1) (tn^-1)] + Cntn/2 where Cn=last quantifiable concentration, tn=time at which Cn is measured, k=rate constant.", 
                "measure": "Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 11 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1"
            }, 
            {
                "description": "The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.", 
                "measure": "Mean Residence Time (MRT) of Bortezomib in the Body on Day 1 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1"
            }, 
            {
                "description": "The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.", 
                "measure": "Mean Residence Time (MRT) of Bortezomib in the Body on Day 11 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1"
            }, 
            {
                "description": "Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).", 
                "measure": "Systemic Clearance (CL) of Bortezomib on Day 1 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1"
            }, 
            {
                "description": "Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).", 
                "measure": "Systemic Clearance (CL) of Bortezomib on Day 11 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by (D/AUC[0-infinity])*(AUMC[0-infinity])/AUC[0-infinity]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time.", 
                "measure": "Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 1 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by (D/AUC[0-infinity])*(AUMC[0-infinity])/AUC[0-infinity]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time.", 
                "measure": "Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 11 of Cycle 1", 
                "safety_issue": "No", 
                "time_frame": "0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01801436"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Johnson & Johnson Taiwan Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johnson & Johnson Taiwan Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2006", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}